Statistical analyses showed that patients with rheumatic diseases (excluding the rituximab/belimumab-treated patients) generated anti-SARS-CoV-2 spike S1 IgG and IgA one month after 2nd dose at a level comparable to healthy control groups (Figure 1E and Supplementary Figure 1B). The gene discussed is CD79A; the disease is rheumatic disorder.